Hyperbaric Chamber for Mental Health: HBOT for Depression, PTSD & TBI

HBOT reduced PTSD symptoms in veterans with a net effect size of 1.64 in a randomized controlled trial using 60 sessions, confirmed by fMRI changes in the prefrontal cortex and hippocampus. A 2026 systematic review of 6 RCTs found consistent reductions in depressive symptoms across trials. The evidence is strongest for PTSD and post-injury depression, weaker for generalized anxiety and ADHD.

Why HBOT Is Being Explored for Mental Health

Mental health conditions have long been understood primarily through the lens of neurotransmitter imbalances. While medications targeting serotonin, dopamine, and norepinephrine remain standard treatments, a growing body of research points to additional biological mechanisms that may contribute to psychiatric disorders. HBOT addresses several of these mechanisms directly.

The Brain-Inflammation Connection

Chronic neuroinflammation has been identified as a contributing factor in depression, PTSD, anxiety, and other mental health conditions. Elevated levels of pro-inflammatory cytokines have been found in patients with major depressive disorder, and inflammation in the brain can disrupt neurotransmitter production and neural signaling. HBOT has well-documented anti-inflammatory effects, reducing inflammatory markers and helping to restore healthier brain environments.³

Neuroplasticity and Brain Repair

HBOT has been shown to stimulate angiogenesis (the growth of new blood vessels) and promote neuroplasticity, the brain’s ability to form new neural connections. This is particularly relevant for conditions like PTSD and TBI-related depression, where brain regions involved in emotional regulation, memory processing, and stress response may have reduced function. By promoting the growth of new neural pathways, HBOT may help the brain recover capacities that have been impaired by trauma or chronic stress.¹

In a randomized controlled trial, 60 HBOT sessions produced significant improvement in treatment-resistant PTSD symptoms in veterans, with a net effect size of 1.64, confirmed by fMRI showing improved activity in the dorsolateral prefrontal cortex, hippocampus, and insula.

Doenyas-Barak et al., PLoS ONE, 2022

Cerebral Blood Flow

Brain imaging studies have consistently shown that patients with depression, PTSD, and ADHD often exhibit reduced blood flow to specific brain regions. HBOT significantly increases oxygen delivery to the brain and has been shown in neuroimaging studies to improve cerebral perfusion. Restoring adequate blood flow to underperforming brain areas may help alleviate symptoms associated with these conditions.

The Mitochondrial Theory of Mental Illness

An emerging area of psychiatric research focuses on mitochondrial dysfunction as a root cause of mental health conditions. Mitochondria are the energy-producing structures within cells, and the brain is the most energy-demanding organ in the body. When mitochondria underperform, brain cells cannot function optimally, potentially contributing to symptoms of depression, brain fog, fatigue, and cognitive impairment. HBOT increases the oxygen available for mitochondrial energy production, which may help restore normal brain cell function.

HBOT for PTSD

Of all mental health applications, HBOT for PTSD has the strongest and most developed evidence base. Several clinical studies, many focused on military veterans, have produced encouraging results.

A 2022 randomized controlled trial published in PLOS ONE studied military veterans with treatment-resistant PTSD. Participants who received 60 HBOT sessions at 2.0 ATA showed significant improvements in CAPS-5 PTSD scores compared to the control group (net effect size 1.64, P<0.0001). Brain fMRI and DTI confirmed structural and functional improvements in regions governing emotional regulation and fear processing.¹

A 2-year longitudinal follow-up of 22 veterans confirmed these benefits persisted. CAPS-5 scores remained significantly improved versus pre-treatment (26.6 vs. 47.5, P<0.001). Employment rates rose from 41% to 73%, partnership rates from 46% to 77%, and benzodiazepine and cannabis use decreased significantly.²

A definitive $28 million, 5-year randomized double-blind placebo-controlled trial enrolling 400+ veterans is currently underway at USF Health to provide the field with higher-powered confirmation.

For a deeper look at the research and treatment protocols, visit our dedicated HBOT for PTSD page.

HBOT for Depression

Research into HBOT for depression is less extensive than the PTSD research, but the biological rationale is strong and early findings are encouraging.

A 2026 randomized sham-controlled trial by Tang et al. enrolled 61 patients with post-stroke depression in a double-blind design. HBOT significantly reduced HAMD depression scores at week 2 (P=0.017) and week 4 (P<0.001) compared to sham, with concurrent elevations in serum BDNF and beta-NGF (P<0.01). Reductions in depression correlated with BDNF increases (r=0.66), providing both clinical and biological evidence of effect.³

A 2026 systematic review of 6 RCTs found HBOT consistently reduced depressive symptoms and improved cognitive and functional outcomes, including when combined with antidepressant medications.⁴

A 2026 systematic review of 6 randomized controlled trials found HBOT consistently reduced depressive symptoms and improved cognitive and functional outcomes, including when combined with standard antidepressant medications.

Ahsan et al., 2026

For a complete review of the evidence, see our full HBOT for depression guide.

HBOT for Anxiety

The evidence for HBOT as a standalone treatment for anxiety disorders is currently limited. Most of the available data comes from studies focused on other primary conditions, where anxiety improvements were observed as a secondary outcome.

In several PTSD and TBI studies, participants reported significant reductions in anxiety alongside improvements in their primary condition. The shared biological mechanisms, particularly neuroinflammation and reduced cerebral blood flow, suggest that treatments addressing these root causes may benefit multiple conditions simultaneously.

At this stage, HBOT’s potential for anxiety is best understood in the context of treating co-occurring conditions rather than as a primary anxiety intervention. Dedicated clinical trials for generalized anxiety disorder, social anxiety, or panic disorder are still lacking.

HBOT for ADHD

The application of HBOT for attention-deficit/hyperactivity disorder is an area of active interest with limited but intriguing evidence. ADHD is associated with reduced blood flow to the prefrontal cortex, the brain region responsible for executive function, attention, and impulse control. A small number of studies, primarily in pediatric populations, have reported improvements in attention, cognitive function, and behavioral measures following HBOT sessions. However, these studies have generally been small, and larger controlled trials are needed before firm conclusions can be drawn.

For a detailed review of the current evidence, visit our HBOT for ADHD page.

HBOT and TBI-Related Mental Health

One of the most important aspects of HBOT’s mental health potential lies in the significant overlap between traumatic brain injury and psychiatric conditions. TBI is one of the strongest risk factors for developing PTSD, depression, and anxiety. Among military veterans and athletes with a history of head injuries, mental health symptoms and TBI effects frequently coexist and compound each other.

HBOT may be uniquely suited to this challenge because it addresses shared biological mechanisms: inflammation, impaired blood flow, and damaged neural tissue. Several studies examining HBOT for mild TBI have reported concurrent improvements in depression scores, anxiety levels, and PTSD symptoms alongside improvements in cognitive function.

Treatment Approaches

There is no single universally accepted HBOT protocol for mental health conditions. Treatment parameters vary based on the specific condition, its severity, and clinical judgment. The published research provides some general guidance.

Pressure: Most mental health studies have used pressures between 1.5 and 2.0 ATA. Some researchers favor 1.5 ATA for neurological and psychiatric applications.

Session duration: Treatment sessions typically last 60 to 90 minutes of oxygen breathing time at pressure.

Number of sessions: Protocols in the published literature generally range from 20 to 60 sessions. PTSD studies have commonly used 40 to 60 session protocols.

Frequency: Most clinical protocols involve daily sessions, five days per week.

For a broader overview of what to expect during treatment, including preparation and session details, see our HBOT sessions guide.

The Current State of Evidence

Honesty about the evidence is essential when discussing HBOT for mental health. Here is where things stand:

What the evidence supports: HBOT shows genuine promise for PTSD, particularly in veterans and individuals with co-occurring TBI. The biological mechanisms through which HBOT could benefit mental health are well-established and scientifically plausible. Multiple clinical studies have demonstrated measurable improvements in both symptoms and brain imaging findings.¹²

What the evidence does not yet support: HBOT cannot currently be recommended as a primary or standalone treatment for any mental health condition. The existing studies, while encouraging, are generally small in scale. Large, multi-site RCTs are needed to establish standardized protocols and confirm efficacy across diverse patient populations.

The responsible perspective: HBOT should be considered as a potential complementary approach, used alongside, not instead of, established mental health treatments such as psychotherapy, medication, and lifestyle interventions. Anyone considering HBOT for a mental health condition should do so in consultation with both a mental health provider and an experienced hyperbaric medicine practitioner.

For ongoing updates on HBOT research across all conditions, visit our HBOT research page.

Who Should Not Try HBOT

HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone. Discuss your full medical history with your provider before starting treatment.

Absolute Contraindications

HBOT should not be used if you have:

• Untreated pneumothorax (collapsed lung) – pressure changes can worsen this condition and become life-threatening
• Certain chemotherapy drugs – bleomycin, cisplatin, doxorubicin, and disulfiram may interact dangerously with high-oxygen environments

Relative Contraindications

Your provider may need to take extra precautions or postpone treatment if you have:

• Upper respiratory infection or sinus congestion – difficulty equalizing pressure can cause ear or sinus barotrauma
• Seizure disorder – high-pressure oxygen can lower seizure threshold in susceptible individuals
• Chronic obstructive pulmonary disease (COPD) – altered breathing drive may require modified protocols
• High fever – increases the risk of oxygen toxicity
• History of ear surgery or chronic ear problems – pressure equalization may be difficult or risky
• Claustrophobia – may require sedation or use of a multiplace chamber instead
• Pregnancy – insufficient safety data exists for routine use during pregnancy

Talk to Your Doctor First

Even if you do not have the conditions listed above, always consult your physician before starting HBOT, especially if you take insulin (blood sugar may drop during treatment), have a pacemaker or implanted device, or are currently taking any medications. For a full overview of HBOT side effects and risks, see our detailed guide.